1st Quarter - Report

RED+BLUE STRATEGIES for HOSPIRA

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Working to ensure that issues related to coding and reimbursement are discussed and addressed to ensure a smooth start to the coverage of biosimilar medications as they enter into the United States' prescription drug market this year.

LobbyistCovered position, as disclosed
MEGAN HAUCK MARSHALL —
MELANIE JAN NATHANSON —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE

Pharmacy PHA

Issues related to the naming of biosimilars as they enter into the national prescription drug marketplace.

LobbyistCovered position, as disclosed
MEGAN HAUCK MARSHALL —
MELANIE JAN NATHANSON —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.